No Data
Ionis (IONS), Biogen Down on Ending Development of ALS Drug
Analysts Are Bullish on These Healthcare Stocks: AN2 Therapeutics, Inc. (ANTX), Heron Therapeutics (HRTX)
Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its First-Quarter Results
Heron Therapeutics, Inc. (NASDAQ:HRTX) just released its latest first-quarter results and things are looking bullish. Results overall were solid, with revenues arriving 5.1% better than analyst f
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2024 Earnings Call Transcript
Needham: Reiterates Heron Therapeutics (HRTX.US) rating, adjusted from buy to buy rating, target price of $5.00.
Needham: Reiterates Heron Therapeutics (HRTX.US) rating, adjusted from buy to buy rating, target price of $5.00.
Needham Reiterates Buy on Heron Therapeutics, Maintains $5 Price Target
Needham analyst Serge Belanger reiterates Heron Therapeutics (NASDAQ:HRTX) with a Buy and maintains $5 price target.